Metsera, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Metsera, Inc. | MTSR - NASDAQ |
$15.00-$17.00 | $18.00 | $25.50 | 15.3 million | 1/31/2025 |
| BofA Securities, Goldman Sachs, Evercore ISI, Guggenheim Securities, Cantor | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2025-01-13 Terms Added 2025-01-27 | ||||||
Metsera, Inc. Quote & Chart - Click for current quote - MTSR
IPO Boutique aggregates information on public companies and private companies, such as "MTSR" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Metsera, Inc. (adapted from Metsera, Inc. prospectus):
They are a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "MTSR" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.